The emergence of tamoxifen for the treatment of ER positive cancer, along with the development of trastuzumab for the treatment of breast cancers overexpressing HER2, has seen the number of breast cancer related deaths reduce significantly [35]. This evidence concerns the gene ERBB2 and breast carcinoma.